Biogen's Alzheimer's drug loses subsidies in the US

The US government is limiting its coverage of Biogen's Alzheimer's drug, Aduhelm, due to the risk of adverse effects. Biogen's stock plummets.
Photo: Pool New/Reuters/Ritzau Scanpix
Photo: Pool New/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading